INTERIM REPORT 中 期 報 告 2025/26 (Incorporated in Bermuda with limited liability) Stock code 股份代號 : 858 Extrawell Pharmaceutical Holdings Limited (於百慕達註冊成立之有限公司) CONTENTS 目錄 Condensed Interim Financial Information 簡明中期財務資料 Board of Directors 董事會 Condensed Consolidated Statement of Financial Position 簡明綜合財務狀況表 2 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 簡明綜合損益及其他全面收益表 4 Condensed Consolidated Statement of Changes in Equity 簡明綜合權益變動表 7 Condensed Consolidated Statement of ...

Core Viewpoint - The company announced the grant of a total of 76.5 million share options to three grantees, all of whom are executive directors, under its share option scheme adopted on September 2, 2022 [1] Group 1 - The share options were granted to three individuals: Cheng Yong, Lou Yi, and Guo Yi, all of whom are executive directors of the company [1] - The announcement was made on December 19, 2025, indicating the company's ongoing commitment to incentivizing its executive team [1]

Group 1 - The company, 精优药业 (00858), announced the grant of a total of 76.5 million stock options to three grantees, all of whom are executive directors [1] - The stock options were granted under a share option plan adopted on September 2, 2022 [1] - The exercise price for the stock options is set at HKD 0.0936 per share [1]

Group 1 - The company, 精优药业 (00858), announced the grant of a total of 76.5 million stock options to three grantees, all of whom are executive directors [1] - The stock option exercise price is set at HKD 0.0936 per share [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 本公告僅供說明用途，並不構成收購、購買或認購本公司任何證券的邀請或要約。 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 授出購股權 本公告乃由精優藥業控股有限公司（「本公司」，連同其附屬公司稱為「本集團」）根據香港聯 合交易所有限公司證券上市規則（「上市規則」）第17.06A條作出。 本公司董事（「董事」）會（「董事會」）宣佈，於二零二五年十二月十九日，本公司根據其於二 零二二年九月二日採納的購股權計劃（「購股權計劃」），向合共三名承授人（ 即程勇先生、樓 屹博士及郭懿博士，彼等均為執行董事（）「承授人」）提呈授出合共76,500,000份購股權（「購 股權」）。 購股權的詳情如下： – 1 – 授出日期 ： 二零二五年十二月十九日（「授出日期」） 授出購股權的行使價 ： 每股0.0936港元，即以下各項的最高者： (i) 於 授 出 日 期 香 港 聯 合 交 易 所 有 限 公 司（「 ...

致：香港交易及結算所有限公司 公司名稱: 精優藥業控股有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年12月3日 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00858 | 說明 | 精優藥業 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.01 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.01 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 主要交易 債券條款及條件之建議第四次修訂 第四份修訂契據 上市規則涵義 由於第四份修訂契據項下擬進行之交易涉及之一項或多項適用百分比率超過25%，故根 據上市規則第14章，第四份修訂契據項下擬進行之交易構成本公司之主要交易。因此， 建議第四次修訂須遵守上市規則第14章項下申報、公告及股東批准之規定。 為給予本公司充足時間編製及落實載入通函的資料以及進行批量印刷程序，載有（ 其中包 括）上市規則規定的有關建議第四次修訂作為主要交易之進一步資料及股東特別大會通告 之通函將於切實可行之情況下盡快於二零二六年三月六日或之前寄發予股東。 – 1 – 警告 股東及有意投資者務請注意，第四份修訂契據須待所有先決條件獲達成後，方可作實。 第四份修訂契據項下擬進行之交易不一定會落實。股東及有意投資者於買賣股份時務請 審慎行事。 背景 茲 提 述 二 零 一 四 ...

Core Viewpoint - The company reported a significant loss for the mid-2025 period, primarily due to unrealized losses on convertible bond investments, contrasting with a profit in the same period of 2024 [1] Financial Performance - The group recorded revenue of approximately 28 million HKD during the mid-2025 period [1] - Loss from continuing operations amounted to about 459 million HKD, compared to a profit of approximately 102 million HKD in the mid-2024 period [1] - The unrealized loss on convertible bond investments was approximately 443 million HKD, classified as other receivables as of September 30, 2025, which is a non-cash item [1] - In the mid-2024 period, the same investment recorded a fair value gain of about 110 million HKD [1] Industry Outlook - The Chinese pharmaceutical market is expected to achieve healthy growth driven by evolving demand for quality medical services and diversified pharmaceutical supply amid structural transformation led by national healthcare reform policies [1] - Despite facing challenges such as strict regulations and intense competition, the company believes there are potential development opportunities in the expanding consumer base within the Chinese pharmaceutical market [1] - The company plans to continuously monitor market trends and explore potential collaborations with strategic partners to develop pharmaceutical and health-related products, aiming to promote long-term development [1]

Core Viewpoint - The company reported a significant decline in revenue and a shift from profit to loss in its interim results for the six months ending September 30, 2025 [1] Financial Performance - Revenue for the period was HKD 28.08 million, representing a year-on-year decrease of 9.04% [1] - The company recorded a loss attributable to shareholders of HKD 460 million, a shift from profit to loss compared to the previous year [1] - Earnings per share were reported at a loss of HKD 0.1909 [1]

Core Points - The company reported a revenue of HKD 28.08 million for the six months ending September 30, 2025, representing a year-on-year decrease of 9.04% [1] - The company experienced a loss attributable to shareholders of HKD 460 million, marking a shift from profit to loss compared to the previous year [1] - The loss per share was HKD 0.1909 [1]